Stocks and Investing Stocks and Investing
Mon, August 3, 2020
Fri, July 31, 2020

Andrew Fein Maintained (VRTX) at Strong Buy with Increased Target to $315 on, Jul 31st, 2020


Published on 2024-10-27 11:13:24 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $295 to $315 on, Jul 31st, 2020.

Andrew has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Increased Target to $300 on, Wednesday, July 8th, 2020


These are the ratings of the 8 analyists that currently disagree with Andrew


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $328 on, Monday, July 20th, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $325 on, Friday, June 12th, 2020
  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $320 on, Friday, May 15th, 2020
  • Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $297 on, Thursday, April 30th, 2020
  • Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $285 on, Thursday, April 30th, 2020
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $305 on, Thursday, April 30th, 2020
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $283 on, Thursday, April 30th, 2020
Contributing Sources